COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study

Yan, Di; Kolla, Avani; Young, Terry-Lynn; Fried, Lisbeth S.; Shankar, Shruthi; Rangel, Lauren K.; Yin, Lu; Castillo, Rochelle; Steuer, Alexa B.; Svigos, Katerina; Izmirly, Peter; Sekar, Vaish; Lesser, Robert L.; Solomon, Gary; Blank, Rebecca B.; Haberman, Rebecca H.; Neimann, Andrea L.; Scher, Jose U.

doi:10.1016/j.jdin.2022.03.011

Cited by 2 publications

(2 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical efficacy of these inhibitors in clinical patients has been observed according to numerous reports. 160 , 161 , 162 Currently, a randomized clinical trial is underway to evaluate the efficacy of risankizumab alone or in combination with remdesivir in COVID‐19 (NCT04583956). Blockade of IL‐17A is another potential option for coronavirus cytokine storm treatment.…”

Section: Repurposing Clinically Available Drugs and Therapies For Pat...mentioning

confidence: 99%

“…IL‐12/23 inhibitors, including risankizumab, guselkumab, tildrakizumab, and ustekinumab, were originally indicated for chronic inflammatory and autoimmune diseases, such as psoriasis and inflammatory bowel disease, 156–159 and are now under investigation as COVID‐19 therapies. The clinical efficacy of these inhibitors in clinical patients has been observed according to numerous reports 160–162 . Currently, a randomized clinical trial is underway to evaluate the efficacy of risankizumab alone or in combination with remdesivir in COVID‐19 (NCT04583956).…”

Section: Repurposing Clinically Available Drugs and Therapies For Pat...mentioning

confidence: 99%

See 1 more Smart Citation

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Xue

Mei

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic has affected a large portion of the global population, both physically and mentally. Current evidence suggests that the rapidly evolving coronavirus subvariants risk rendering vaccines and antibodies ineffective due to their potential to evade existing immunity, with enhanced transmission activity and higher reinfection rates that could lead to new outbreaks across the globe. The goal of viral management is to disrupt the viral life cycle as well as to relieve severe symptoms such as lung damage, cytokine storm, and organ failure. In the fight against viruses, the combination of viral genome sequencing, elucidation of the structure of viral proteins, and identifying proteins that are highly conserved across multiple coronaviruses has revealed many potential molecular targets. In addition, the time‐ and cost‐effective repurposing of preexisting antiviral drugs or approved/clinical drugs for these targets offers considerable clinical advantages for COVID‐19 patients. This review provides a comprehensive overview of various identified pathogenic targets and pathways as well as corresponding repurposed approved/clinical drugs and their potential against COVID‐19. These findings provide new insight into the discovery of novel therapeutic strategies that could be applied to the control of disease symptoms emanating from evolving SARS‐CoV‐2 variants.

show abstract

Section: Repurposing Clinically Available Drugs and Therapies For Pat...mentioning

confidence: 99%

Section: Repurposing Clinically Available Drugs and Therapies For Pat...mentioning

confidence: 99%

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Xue

Mei

Chen

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

Managing psoriatic arthritis in different clinical scenarios

Queiro,

Loredo,

Braña

et al. 2023

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study

Cited by 2 publications

References 4 publications

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2

Managing psoriatic arthritis in different clinical scenarios

Contact Info

Product

Resources

About